BNP Paribas Financial Markets Acquires 57,393 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

BNP Paribas Financial Markets boosted its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 1,184.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,238 shares of the biopharmaceutical company’s stock after buying an additional 57,393 shares during the period. BNP Paribas Financial Markets owned approximately 0.11% of Vanda Pharmaceuticals worth $292,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of VNDA. Monaco Asset Management SAM bought a new position in shares of Vanda Pharmaceuticals in the second quarter worth $1,090,000. Massachusetts Financial Services Co. MA purchased a new stake in Vanda Pharmaceuticals during the 3rd quarter worth about $864,000. Dimensional Fund Advisors LP boosted its stake in Vanda Pharmaceuticals by 17.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock worth $11,379,000 after purchasing an additional 292,172 shares during the period. GSA Capital Partners LLP purchased a new position in Vanda Pharmaceuticals during the 3rd quarter valued at about $143,000. Finally, Nantahala Capital Management LLC increased its position in shares of Vanda Pharmaceuticals by 57.3% during the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock valued at $9,003,000 after buying an additional 580,265 shares during the period. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Stock Down 0.2 %

NASDAQ:VNDA opened at $4.61 on Monday. The stock has a market cap of $268.80 million, a P/E ratio of -16.46 and a beta of 0.76. The business’s 50-day moving average price is $4.84 and its two-hundred day moving average price is $5.23. Vanda Pharmaceuticals Inc. has a twelve month low of $3.46 and a twelve month high of $6.75.

Insider Buying and Selling

In other news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the sale, the director now directly owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. The trade was a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 8.90% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on VNDA shares. HC Wainwright started coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, October 31st. They issued a “buy” rating and a $18.00 price objective for the company. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 11th. They issued a “hold” rating on the stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.